There are currently 60 clinical trials in Athens, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including University Cancer and Blood Center LLC, University of Georgia, University Cancer & Blood Center, LLC and Northeast Georgia Cancer Care, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Mechanisms of Uterine Fluid Absorption During Early Pregnancy ( ELF Study)
NCT06847685
Recruiting
The researchers are evaluating mechanisms of uterine fluid absorption during early pregnancy
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/05/2025
Locations: University of Georgia, Athens, Georgia
Conditions: Endometriosis, Endometrioma
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Summit Clinical Research, LLC, Athens, Georgia
Conditions: Diabetic Gastroparesis
Register for Updates
Cognitive Training for Emotion Regulation in Psychotic Disorders
NCT04414215
Recruiting
The current study examines the efficacy of a cognitive training intervention for improving emotion regulation in psychotic disorders. it is hypothesized that the cognitive training program will enhance prefrontal activation, leading to enhanced emotion regulation.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/04/2025
Locations: University of Georgia, Athens, Georgia
Conditions: Schizophrenia, Schizo Affective Disorder
Register for Updates
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167
Recruiting
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Exelixis Clinical Site #123, Athens, Georgia
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Athens, Georgia
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
NCT05249101
Recruiting
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: University Cancer and Blood Center, Athens, Georgia
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: University Cancer and Blood Center LLC, Athens, Georgia
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users
NCT05447325
Recruiting
180 young adult vapers who are not current smokers will participate in a baseline functional magnetic resonance imaging (fMRI) experiment, prospectively linked to a 1-year randomized controlled trial. Baseline fMRI tasks will probe critical neurocognitive markers with high potential to account for individual differences in nicotine use prognosis and responsiveness to anti-vaping public service announcements (PSAs). Participants will be assigned randomly to a survey-only control condition, or one... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
12/21/2024
Locations: UGA Bio-imaging Research Center, Athens, Georgia
Conditions: Message Exposure (Sequence: Regular Then Flavor), Message Exposure (Sequence: Flavor Then Regular), No Message Exposure (Control Condition)
Register for Updates
Carbohydrates and Running Performance
NCT06742398
Recruiting
Carbohydrates serve as the body's primary energy source during intense exercise, and consuming carbohydrates during exercise has been shown to improve exercise performance. Previous research has shown that the presence of carbohydrates in the mouth activates sweet taste receptors on the tongue, which signal the brain to increase neural activation in areas associated with motor functioning, sensory perception, and reward centers during exercise through this CPR. The primary objective of this inte... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/18/2024
Locations: University of Georgia, Athens, Georgia
Conditions: Nutrition, Healthy
Register for Updates
Effects of an Antioxidant Supplement on Blood Vessel Health
NCT06424756
Recruiting
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysf... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/04/2024
Locations: Ramsey Student Center, University of Georgia, Athens, Georgia
Conditions: Healthy
Register for Updates
Dose Response Effects of Pecan Consumption
NCT05949879
Recruiting
The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. The s... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
12/03/2024
Locations: University of Georgia, Athens, Georgia
Conditions: Dyslipidemias, Overweight and Obesity, Nutrition, Healthy
Register for Updates
Cottonseed Oil Versus Matched PUFA Effects
NCT06382298
Recruiting
Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. Cottonseed oil (CSO) is found readily in the food supply, and the investigator's previous studies have demonstrated that incorporating CSO into the diet is sufficient to improve fasting cholesterol profile and improve postprandial lipid and/or glycemic responses in both healthy, and at-risk populations. This study aims to compare C... Read More
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
12/03/2024
Locations: University of Georgia, Athens, Georgia
Conditions: Dyslipidemia, Overweight and Obesity, Nutrition, Healthy
Register for Updates